Sedative-like effect of intraperitoneal GABA administration in the open field test

Resumen

Gamma-Amino Butyric Acid (GABA) is the main
inhibitor neurotransmitter of the Central Nervous System (CNS). Its
peripheral administration has been matter of discussion. On the one
hand, it has been reported that it does not cross the Blood-Brain
Barrier (BBB), and, on the other hand, it has been associated with
multiple therapeutic regimens and supplements by peripheral
administration. The aim of the present study is to elucidate the
possibility of a central sedative effect when administered
peripherally. An experimental cohort of 90-day-old Holtzman male
rats weighing 240-270 g was used. It was divided into 2 groups:
saline-controls (n = 9) and GABA treated rats (12.5 mg/kg, n = 9).
Both groups were intraperitoneally injected. The motor behavioral
patterns displayed in the Opto Varimex (OVM) were studied.
Vertical, horizontal, ambulatory and non-ambulatory movements
and the number of movements were recorded in an automated way.
Horizontal movements constitute the integration of ambulatory and
non-ambulatory movements. Student t test was used comparing
groups. In this experiment, there were non-significant downward
trends in vertical, ambulatory, non-ambulatory and number of
movements. Ambulatory and non-ambulatory tendencies acquired
significance when treated together as horizontal movements
(p < 0.05). We may conclude that peripheral administration of
GABA produced a decrease of the horizontal movements in the open
field test. It may be interpreted as a sedative effect, suggesting a
passage of GABA through BBB, with central effects. However,
there are several alternative possibilities to explain present findings.
Other experiments will elucidate the implications or scope of the
present findings.

Citas

1. Al-Sarraf, H. Transport of 14C-gamma
2. aminobutyric acid into brain, cerebrospinal fluid
3. and choroid plexus in neonatal and adult rats.
4. Brain. Res. Dev. Brain Res., v. 139, no. 2,
5. p. 121-129, 2002.
6. Baxter, C. F.; Roberts, E. The gamma
7. aminobutyric
8. acid-alpha-ketoglutaric
9. acid
10. transaminase of beef brain. J. Biol. Chem.,
11. v. 233, no. 5, p. 1135-1139, 1958.
12. Blackshaw, L. A. Receptors and transmission in
13. the brain-gut axis: potential for novel therapies.
14. IV. GABA(B) receptors in the brain
15. gastroesophageal axis. Am. J. Physiol.
16. Gastrointest. Liver Physiol., v. 281, no. 2,
17. p. G311-G315, 2001.
18. Boonstra, E.; de Kleijn, R.; Colzato, L. S.;
19. Alkemade, A.; Forstmann, B. U.; Nieuwenhuis,
20. S. Neurotransmitters as food supplements: the
21. effects of GABA on brain and behavior. Front.
22. Psychol., v. 6, p. 1520, 2015.
23. Dinan, T. G.; Stanton, C.; Cryan, J. F.
24. Psychobiotics: a novel class of psychotropic.
25. Biol. Psychiatry, v. 74, no. 10, p. 720-726,
26. Elliot, K. A.; Van Gelder, N. M. Occlusion and
27. metabolism of gamma-aminobutyric acid by
28. brain tissue. J. Neurochem., v. 3, no. 1,
29. p. 28-40, 1958.
30. Feng, M. R.; Turluck, D.; Burleigh, J.; Lister,
31. R.; Fan, C.; Middlebrook, A.; Taylor, C.; Su, T.
32. Brain microdialysis and PK/PD correlation of
33. pregabalin in rats. Eur. J. Drug Metab.
34. Pharmacokinet., v. 26, no. 1-2, p. 123-128,
35. Frey, H. H.; Löscher, W. Cetyl GABA: effect
36. on convulsant thresholds in mice and acute
37. toxicity. Neuropharmacology, v. 9, no. 2,
38. p. 217-220, 1980.
39. Gargiulo, P. A.; Viana, M. B.; Graeff, F. G.;
40. Silva, M. A.; Tomaz, C. Effects of anxiety and
41. memory of systemic and intra-amygdala
42. injection of 5-HT3 receptor antagonist BRL
43. A. Neuropsychobiology, v. 33, no. 4,
44. p. 189-195, 1996.
45. Halson, S. L. Sleep in elite athletes and
46. nutritional interventions to enhance sleep.
47. Sports Med., v. 44, Suppl. 1, p. S13-S23, 2014.
48. Jones, E. A.; Schafer, D. F.; Ferenci, P.; Pappas,
49. S. C. The GABA hypothesis of the pathogenesis
50. of hepatic encephalopathy: current status. Yale
51. J. Biol. Med., v. 57, no. 3, p. 301-316, 1984.
52. Knudsen, G. M.; Poulsen, H. E.; Paulson, O. B.
53. Blood-brain
54. barrier
55. permeability
56. in
57. galactosamine-induced hepatic encephalopathy.
58. No evidence for increased GABA-transport.
59. J. Hepatol., v. 6, no. 2, p. 187-192, 1988.
60. Kuriyama, K.; Sze, P.Y. Blood-brain barrier to
61. H3-gamma-aminobutyric acid in normal and
62. amino
63. oxyacetic acid-treated
64. animals.
65. Neuropharmacology, v. 10, no. 1, p. 103-108,
66. Llano López, L. H.; Caif, F.; Fraile, M.;
67. Tinnirello, B.; Gargiulo, A. I.; Lafuente, J. V.;
68. Baiardi, G. C.; Gargiulo P. A. Differential
69. behavioral profile induced by the injection of
70. dipotassium chlorazepate within brain areas that
71. project to the nucleus accumbens septi.
72. Pharmacol. Rep., v. 65, no. 3, p. 566-578,
73. Llano López, L. H.; Caif, F.; García, S.; Fraile,
74. M.; Landa, A. I.; Baiardi, G.; Lafuente, J. V.;
75. Braszko, J. J.; Bregonzio, C.; Gargiulo, P. A.
76. Anxiolytic-like effect of losartan injected into
77. amygdala of the acutely stressed rats.
78. Pharmacol. Rep., v. 64, no. 1, p. 54-63, 2012.
79. Löscher, W. Effect of inhibitors of GABA
80. aminotransferase on the metabolism of GABA
81. in brain tissue and synaptosomal fractions.
82. J. Neurochem., v. 36, no. 4, p. 1521-1527,
83. Löscher, W.; Frey, H. H. Transport of GABA at
84. the blood-CSF interface. J. Neurochem., v. 38,
85. no. 4, p. 1072-1079, 1982.
86. Maj, J.; Przewlocka, B.; Kukulka, L. Sedative
87. action of low doses of dopaminergic agents.
88. Pol. J. Pharmacol. Pharm., v. 29, no. 1,
89. p. 11-21, 1977.
90. Marinzalda, M. L.; Pérez, P. A.; Gargiulo, P. A.;
91. Casarsa, B.S.; Bregonzio, C.; Baiardi, G. Fear
92. potentiated behaviour is modulated by central
93. amygdala angiotensin II AT1 receptors
94. stimulation. Biomed. Res. Int., v. 2014,
95. Article ID 183248,
96. p.,
97. http://dx.doi.org/10.1155/2014/183248
98. Martínez, G.; Ropero, C.; Funes, A.; Flores, E.;
99. Blotta, C.; Landa, A. I.; Gargiulo, P. A. Effects
100. of selective NMDA and non-NMDA blockade
101. Braz. J. Biol. Sci., 2016, v. 3, no. 6, p. 257-262.
102. Gargiulo et al.
103. in the nucleus accumbens on the plus-maze test.
104. Physiol. Behav., v. 76, no. 2, p. 219-224,
105. a.
106. Martínez, G.; Ropero, C.; Funes, A.; Flores, E.;
107. Landa, A. I.; Gargiulo, P. A. AP-7 into the
108. nucleus accumbens disrupts acquisition but does
109. not affect consolidation in a passive avoidance
110. task. Physiol. Behav., v. 76, no. 2, p. 205-212,
111. b.
112. Mayer, E. A.; Tillisch, K.; Gupta, A. Gut/brain
113. axis and the microbiota. J. Clin. Invest., v. 125,
114. no. 3, p. 926-938, 2015.
115. Mesones, H. L.; Cia, F. M. Correlation between
116. clinical and laboratory data in depression.
117. Therapeutic orientation by means of vitamins
118. and amino acids. Acta Psiquiatr. Psicol. Am.
119. Lat., v. 31, no. 1, p. 25-36, 1985.
120. Morita, S.; Miyata S. Different vascular
121. permeability between the sensory and secretory
122. circumventricular organs of adult mouse brain.
123. Cell Tissue Res., v. 349, no. 2, p. 589-603,
124. Morris, G. L. Gabapentin. Epilepsia, v. 40,
125. Suppl. 5, p. S63-S70, 1999.
126. Patterson, E.; Cryan, J. F.; Fitzgerald, G. F.;
127. Ross, R. P.; Dinan, T. G.; Stanton, C. Gut
128. microbiota, the pharmabiotics they produce and
129. host health. Proc. Nutr. Soc., v. 73. no. 4,
130. p. 477-489, 2014.
131. Roberts, E.; Lowe, I. P.; Guth, L.; Jelinek, B.
132. Distribution of γ-aminobutyric acid and other
133. aminoacids in nervous tissue of various species.
134. J. Exp. Zool., v. 138, p. 313-328, 1958.
135. Roberts, E.; Kuriyama, K. Biochemical
136. physiological correlations in studies of the
137. gamma-aminobutyric acid system. Brain Res.,
138. v. 8, no. 1, p. 1-35, 1968.
139. Rodríguez, E. M.; Blázquez, J. L.; Guerra, M.
140. The design of barriers in the hypothalamus
141. allows the median eminence and the arcuate
142. nucleus to enjoy private milieus: the former
143. opens to the portal blood and the latter to the
144. cerebrospinal fluid. Peptides, v. 31, no. 4,
145. p. 757-776, 2010.
146. Sapru, H. N. Role of the hypothalamic arcuate
147. nucleus in cardiovascular regulation. Auton.
148. Neurosci., v. 175, no. 1/2, p. 38-50, 2013.
149. Scott, L. V.; Clarke, G.; Dinan, T. G. The brain
150. gut axis: a target for treating stress-related
151. disorders. Mod. Trends Pharmacopsychiatry,
152. v. 28,
153. p. 90-99,
154. http://dx.doi.org/10.1159/000343971
155. Shyamaladevi, N.; Jayakumar, A. R.; Sujatha,
156. R.; Paul, V.; Subramanian, E. H. Evidence that
157. nitric oxide production increases gamma-amino
158. butyric acid permeability of blood-brain barrier.
159. Brain Res. Bull., v. 57, no. 2, p. 231-236, 2002.
160. Van Gelder, N. M.; Elliot, K. A. Disposition of
161. gamma-aminobutyric acid administered to
162. mammals. J. Neurochem., v. 3, no. 2, p. 139
163. , 1958.
164. Waagepetersen,
165. H. S.;
166. Sonnewald,
167. U.;
168. Schousboe, A. The GABA paradox: multiple
169. roles as metabolite, neurotransmitter, and
170. neurodifferentiative agent. J. Neurochem.,
171. v. 73, no. 4, p. 1335-1342, 1999.
172. Wall, R.; Cryan, J. F.; Ross, R. P.; Fitzgerald,
173. G. F.; Dinan, T. G.; Stanton, C. Bacterial
174. neuroactive
175. compounds
176. produced
177. by
178. psychobiotics. In: Lyte, M.; Cryan, J. F. (Eds.).
179. Microbial endocrinology: the microbiota-gut
180. brain axis in health and disease. New York:
181. Springer, 2014. p. 221-239. (Advances in
182. Experimental Medicine and Biology: Microbial
183. Endocrinology,
184. v. 817).
185. http://dx.doi.org/10.1007/978-1-4939-0897-4_10